Finch Therapeutics Group, Inc.

Equities

FNCH

US31773D2009

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.32 ^USD	+3.57%		+3.57%	-35.73%

Mar. 25	Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 12	Top Premarket Decliners	MT

Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 25, 2024 at 04:31 pm EDT

Finch Therapeutics Group, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 0.107 million compared to USD 0.861 million a year ago. Net loss was USD 74.75 million compared to USD 114.65 million a year ago.

Basic loss per share from continuing operations was USD 46.59 compared to USD 72.12 a year ago.

Latest news about Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Top Premarket Decliners	Mar. 12	MT
North American Morning Briefing : Stocks Seen -2-	Nov. 15	DJ
Finch Therapeutics Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
Finch Therapeutics Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Finch Therapeutics Group, Inc. Announces Resignation of Nicholas Haft as Member of Board	23-06-23	CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell Microcap Index	23-06-23	CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell Microcap Value Index	23-06-23	CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell 3000E Value Index	23-06-23	CI
Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell 3000E Index	23-06-23	CI
Top Premarket Decliners	23-06-13	MT
Finch Therapeutics Group Slumps Almost 15% in Premarket Tuesday	23-06-13	MT
Finch Therapeutics Group to Implement 1-for-30 Reverse Stock Split	23-06-09	MT
Finch Therapeutics Group, Inc. Enters into Lease Termination Agreement with NRL WCS 200 Inner Belt Prop, LLC	23-05-18	CI
Finch Therapeutics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Earnings Flash (FNCH) FINCH THERAPEUTICS GROUP Posts Q1 Revenue $107,000	23-05-10	MT
Finch Therapeutics Group, Inc. Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2023	23-05-10	CI
Finch Therapeutics Appoints Matthew Blischak CEO, Lance Thibault CFO	23-04-26	MT
Finch Therapeutics Group, Inc. Announces Executive Leadership Transitions	23-04-25	CI
Finch Therapeutics Group, Inc. Appoints Lance Thibault as Chief Financial Officer, Effective May 16, 2023	23-04-25	CI
Finch Therapeutics Group, Inc. Announces Executive Changes	23-04-25	CI
Finch Therapeutics Reports Clinical Collaboration in Ulcerative Colitis; Shares Soar After-Hours	23-04-18	MT
Finch Therapeutics Group, Inc. Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women's Hospital and Updates to University of Minnesota License Agreement	23-04-18	CI
Earnings Flash (FNCH) FINCH THERAPEUTICS GROUP Posts Q4 Revenue $8,000	23-03-23	MT

Chart Finch Therapeutics Group, Inc.

Duration

Period

More charts

Company Profile

Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 113 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. Its assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohnâs disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
FINCH THERAPEUTICS GROUP, INC.	-35.73%	3.73M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research